(Updated - October 2, 2026 6:55 AM EDT)

Wedbush analyst Robert Driscoll downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Foghorn Therapeutics (FHTX) PT Lowered to $5 at H.C. WainwrightOctober 2, 2026 6:54 AM Foghorn Therapeutics (FHTX) PT Lowered to $5 at GuggenheimOctober 2, 2026 6:45 AM BTIG Downgrades Foghorn Therapeutics (FHTX) to NeutralOctober 1, 2026 4:38 PM TD Cowen Downgrades Foghorn Therapeutics (FHTX) to HoldOctober 1, 2026 4:08 PM Citizens Downgrades Foghorn Therapeutics (FHTX) to Market PerformOctober 1, 2026 2:55 PM Foghorn Therapeutics (FHTX) PT Lowered to $5 at StifelOctober 1, 2026 12:44 PM Foghorn cuts 40% of staff after FHD-909 trial falls shortOctober 1, 2026 7:02 AM Form 8-K Foghorn Therapeutics For: Sep 25October 1, 2026 7:01 AM Foghorn Therapeutics Provides Update on FHD-909 and Strategic PrioritiesOctober 1, 2026 7:00 AM